|
US7037922B1
(en)
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
ATE247652T1
(de)
|
1999-03-29 |
2003-09-15 |
Neurogen Corp |
4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
|
|
ES2248084T3
(es)
|
1999-06-14 |
2006-03-16 |
Eli Lilly And Company |
Inhibidores de serinproteasa.
|
|
US6794393B1
(en)
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
JP3822494B2
(ja)
|
1999-10-19 |
2006-09-20 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害剤
|
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6420382B2
(en)
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
WO2002032861A2
(en)
|
2000-10-17 |
2002-04-25 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
|
GB0028964D0
(en)
*
|
2000-11-28 |
2001-01-10 |
Smithkline Beecham Spa |
Novel compounds
|
|
AU2002361577A1
(en)
|
2001-10-30 |
2003-05-12 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2004002484A1
(ja)
*
|
2002-06-26 |
2004-01-08 |
Kyowa Hakko Kogyo Co., Ltd. |
ホスホジエステラーゼ阻害剤
|
|
DE602004028678D1
(de)
|
2003-01-28 |
2010-09-23 |
Ironwood Pharmaceuticals Inc |
Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
RU2229475C1
(ru)
*
|
2003-03-06 |
2004-05-27 |
ООО "Исследовательский институт химического разнообразия |
6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
|
|
TW200804288A
(en)
|
2005-12-12 |
2008-01-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
|
WO2008154207A1
(en)
*
|
2007-06-08 |
2008-12-18 |
The Burnham Institute For Medical Research |
Methods and compounds for regulating apoptosis
|
|
CA2930674A1
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
JP2011528375A
(ja)
|
2008-07-16 |
2011-11-17 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
|
KR20220042487A
(ko)
|
2008-12-31 |
2022-04-05 |
알데릭스, 인코포레이티드 |
체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
JP6392754B2
(ja)
|
2012-08-21 |
2018-09-19 |
アーデリクス，インコーポレーテッド |
体液貯留又は塩過負荷に関係する疾患及び消化管疾患の治療におけるｎｈｅ仲介の逆輸送を阻害するための化合物並びに方法
|
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
BR112015025805A2
(pt)
|
2013-04-12 |
2017-07-25 |
Ardelyx Inc |
compostos de ligação de nh3 e métodos para inibir o transporte de fosfato
|
|
WO2014170648A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
EP4424697A3
(en)
|
2013-06-05 |
2024-12-25 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
ES2726927T3
(es)
*
|
2014-07-08 |
2019-10-10 |
Dow Agrosciences Llc |
Proceso para la preparación de ácidos 3-hidroxipicolínicos
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
WO2018129552A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds useful for treating gastrointestinal tract disorders
|
|
BR112019013963A2
(pt)
|
2017-01-09 |
2020-04-28 |
Ardelyx Inc |
inibidores de antiporte mediado por nhe
|
|
JPWO2020101017A1
(ja)
*
|
2018-11-15 |
2021-09-30 |
国立大学法人九州大学 |
Ｉｌ−３１介在性疾患の予防又は治療剤及び医薬組成物
|